These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31303746)

  • 1. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy.
    Tsubota K; Usui Y; Wakabayashi Y; Suzuki J; Ueda S; Goto H
    Clin Ophthalmol; 2019; 13():1063-1070. PubMed ID: 31303746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.
    Park DH; Shin JP; Kim SY
    Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):641-50. PubMed ID: 20012643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab.
    Hu X; Pan Q; Zheng J; Song Z; Zhang Z
    BMC Ophthalmol; 2019 Sep; 19(1):200. PubMed ID: 31519158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
    Wakabayashi Y; Usui Y; Tsubota K; Ueda S; Umazume K; Muramatsu D; Goto H
    Retina; 2017 Dec; 37(12):2317-2325. PubMed ID: 28098727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
    Wakabayashi Y; Usui Y; Okunuki Y; Ueda S; Kimura K; Muramatsu D; Kezuka T; Goto H
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6403-10. PubMed ID: 22899753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
    Feng J; Li B; Wen J; Jiang Y
    Ophthalmic Res; 2018; 60(4):250-257. PubMed ID: 30380554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
    Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
    Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
    Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.
    Ahn J; Woo SJ; Chung H; Park KH
    Ophthalmology; 2011 Nov; 118(11):2218-26. PubMed ID: 21724263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and vitreous vascular endothelial growth factor levels in diabetic retinopathy.
    Sozen-Delil FI; Cekic O; Haklar G
    Int Ophthalmol; 2023 Jul; 43(7):2247-2255. PubMed ID: 36580154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
    di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Ferenchak K; Duval R; Cohen JA; MacCumber MW
    Retina; 2014 Jun; 34(6):1177-81. PubMed ID: 24457977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
    Sato T; Morita S; Bando H; Sato S; Ikeda T; Emi K
    Middle East Afr J Ophthalmol; 2013; 20(1):51-5. PubMed ID: 23580852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.
    Li JK; Wei F; Jin XH; Dai YM; Cui HS; Li YM
    Int J Ophthalmol; 2015; 8(6):1202-6. PubMed ID: 26682173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
    Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
    Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Bevacizumab Injection before Vitrectomy on Intravitreal Hemorrhage in Pseudophakic Patients with Proliferative Diabetic Retinopathy.
    Demir M; Oba E; Can E; Kara O; Cinar S
    Ophthalmol Eye Dis; 2013; 5():11-5. PubMed ID: 23926440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
    Manabe A; Shimada H; Hattori T; Nakashizuka H; Yuzawa M
    Retina; 2015 Sep; 35(9):1800-7. PubMed ID: 25932549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.